These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34818263)

  • 1. Comparing Prognosis Associated with Partial Cystectomy and Trimodal Therapy for Muscle-Invasive Bladder Cancer Patients.
    Su Q; Gao S; Lu C; Wu X; Zuo L; Zhang L
    Urol Int; 2023; 107(1):46-57. PubMed ID: 34818263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.
    Williams SB; Shan Y; Jazzar U; Mehta HB; Baillargeon JG; Huo J; Senagore AJ; Orihuela E; Tyler DS; Swanson TA; Kamat AM
    JAMA Surg; 2018 Oct; 153(10):881-889. PubMed ID: 29955780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative survival analysis of bladder preservation therapy versus radical cystectomy in muscle-invasive bladder cancer.
    Kang NW; Feng YH; Lin KL; Chen YC; Ho CH; Yang CC
    Cancer Med; 2024 Jan; 13(2):e6972. PubMed ID: 38379322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
    Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
    BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic variations between 'primary' and 'progressive' muscle-invasive bladder cancer following radical cystectomy: a novel propensity score-based multicenter cohort study.
    Lai S; Liu J; Lai CH; Seery S; Hu H; Wang M; Hu H; Xu T
    Int J Surg; 2024 Jan; 110(1):270-279. PubMed ID: 37738002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
    J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
    Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
    BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
    Cahn DB; Handorf EA; Ghiraldi EM; Ristau BT; Geynisman DM; Churilla TM; Horwitz EM; Sobczak ML; Chen DYT; Viterbo R; Greenberg RE; Kutikov A; Uzzo RG; Smaldone MC
    Cancer; 2017 Nov; 123(22):4337-4345. PubMed ID: 28743162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients.
    Kijima T; Tanaka H; Koga F; Masuda H; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
    BJU Int; 2019 Aug; 124(2):242-250. PubMed ID: 30811784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoradiation Vs Radical Cystectomy for Muscle-invasive Bladder Cancer: A Propensity Score-weighted Comparative Analysis Using the National Cancer Database.
    Kaushik D; Wang H; Michalek J; Liss MA; Liu Q; Jha RP; Svatek RS; Mansour AM
    Urology; 2019 Nov; 133():164-174. PubMed ID: 31401220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of routine preoperative blood parameters in muscle-invasive bladder cancer.
    Zhang J; Zhou X; Ding H; Wang L; Liu S; Liu Y; Chen Z
    BMC Urol; 2020 Mar; 20(1):31. PubMed ID: 32192483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer.
    Nagao K; Hara T; Nishijima J; Shimizu K; Fujii N; Kobayashi K; Kawai Y; Inoue R; Yamamoto Y; Matsumoto H; Matsuyama H
    Urol Int; 2017; 99(4):446-452. PubMed ID: 28628910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors and oncological outcomes of urethral recurrence in male patients with muscle invasive bladder cancer after radical cystectomy combined with urinary diversion: a propensity score-matched case control study.
    Yao Z; Jiang Y; Zhu X; Wu B; Bai S
    Int J Clin Oncol; 2020 Jul; 25(7):1377-1384. PubMed ID: 32318904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes.
    Mistretta FA; Cyr SJ; Luzzago S; Mazzone E; Knipper S; Palumbo C; Tian Z; Nazzani S; Saad F; Montanari E; Tilki D; Briganti A; Shariat SF; de Cobelli O; Karakiewicz PI
    Clin Genitourin Cancer; 2020 Apr; 18(2):129-137.e3. PubMed ID: 32001182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Maximal Transurethral Resection Preceding Partial Cystectomy for Muscle-Invasive Bladder Cancer.
    Ham WS; Park JS; Jang WS; Kim J
    Ann Surg Oncol; 2024 Feb; 31(2):1384-1392. PubMed ID: 37884699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
    Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
    J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy.
    Koie T; Ohyama C; Yamamoto H; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Kitayam M; Hirota K
    Urol Oncol; 2014 Aug; 32(6):820-5. PubMed ID: 24951323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bladder sparing surgery in high-grade bladder cancer.
    Yakovlev PG; Klyushin DA; Vereshchako RI
    Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival.
    Tang Y; Lin L; Xiao Y; Meng L; Yang Y; Li X
    Clin Transl Oncol; 2024 Feb; 26(2):446-455. PubMed ID: 37389736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.
    Ma B; Li H; Zhang C; Yang K; Qiao B; Zhang Z; Xu Y
    Eur J Surg Oncol; 2013 Oct; 39(10):1150-6. PubMed ID: 23721764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.